Skip to Main Content

Browse issues

Clinical Infectious Diseases Cover Image for Volume 76, Issue 2
Volume 76, Issue 2
15 January 2023
ISSN 1058-4838
EISSN 1537-6591

Volume 76, Issue 2, 15 January 2023

In the Literature

Stan Deresinski
Clinical Infectious Diseases, Volume 76, Issue 2, 15 January 2023, Pages i–ii, https://doi.org/10.1093/cid/ciac839

Major Articles and Commentaries

Saoussen Ben Abdallah and others
Clinical Infectious Diseases, Volume 76, Issue 2, 15 January 2023, Pages 185–191, https://doi.org/10.1093/cid/ciac807

In this randomized controlled trial, we demonstrated that zinc administered orally to hospitalized patients with COVID-19 could prevent intensive care unit admission and reduce the hospital length of stay. For outpatients, zinc could shorten symptom duration.

Marco Vinceti and others
Clinical Infectious Diseases, Volume 76, Issue 2, 15 January 2023, Pages 192–193, https://doi.org/10.1093/cid/ciac849
Eric C Tang and others
Clinical Infectious Diseases, Volume 76, Issue 2, 15 January 2023, Pages 194–200, https://doi.org/10.1093/cid/ciac805

A total of 149 disseminated gonococcal infection (DGI) cases in California were identified; most were aged ≥40 years, heterosexual, or did not present with urogenital symptoms. All isolates with reported results were susceptible to ceftriaxone and cefixime. Expanding gonorrhea screening may prevent DGI.

Sarah Fidler and others
Clinical Infectious Diseases, Volume 76, Issue 2, 15 January 2023, Pages 201–209, https://doi.org/10.1093/cid/ciac796

People with human immunodeficiency virus (HIV) on antiretroviral therapy (ART) with good CD4 T-cell counts make effective cross variant immune responses following third dose vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Sanyog G Shitole and others
Clinical Infectious Diseases, Volume 76, Issue 2, 15 January 2023, Pages 210–219, https://doi.org/10.1093/cid/ciac795

Women with human immunodeficiency virus (HIV; WWH) have an approximately 1.7-fold risk of left ventricular (LV) systolic dysfunction compared with women without HIV. Low CD4+ T-cell counts in WWH are associated with isolated LV diastolic dysfunction, LV hypertrophy, left atrial enlargement, and pulmonary hypertension.

Sebastian Otero and others
Clinical Infectious Diseases, Volume 76, Issue 2, 15 January 2023, Pages 220–228, https://doi.org/10.1093/cid/ciac793

There are higher and longer lasting antibodies in pregnant persons and higher antibody levels in cord blood after COVID-19 vaccination compared with SARS-CoV-2 infection, especially in cases of lower disease severity. Antibody levels wane over time following vaccination and infection.

Courtney L Luterbach and others
Clinical Infectious Diseases, Volume 76, Issue 2, 15 January 2023, Pages 229–237, https://doi.org/10.1093/cid/ciac791

We characterized clusters of carbapenem-resistant Klebsiella pneumoniae among patients in US hospitals using static and dynamic methodologies of clustering. Widespread intrasystem and intersystem transmission was identified. Use of different methods to assess clustering resulted in only minor differences in interpretation.

Jung Seop Eom and others
Clinical Infectious Diseases, Volume 76, Issue 2, 15 January 2023, Pages 238–244, https://doi.org/10.1093/cid/ciac789

This randomized trial compared the diagnostic efficacies of thin and thick bronchoscopes for pulmonary tuberculosis. Bronchial washing using a thin bronchoscope increased the tuberculosis detection rate in patients with pulmonary tuberculosis compared to a conventional, thick bronchoscope.

Davit Baliashvili and others
Clinical Infectious Diseases, Volume 76, Issue 2, 15 January 2023, Pages 245–251, https://doi.org/10.1093/cid/ciac786

In this large-scale, population-based cohort study we found that both treated and untreated hepatitis C are associated with active tuberculosis (TB). People with hepatitis C should be considered for TB-preventive measures, such as treatment for latent TB infection.

Ana Florea and others
Clinical Infectious Diseases, Volume 76, Issue 2, 15 January 2023, Pages 252–262, https://doi.org/10.1093/cid/ciac785

Among immunocompetent adults, the messenger RNA (mRNA)-1273 booster conferred additional protection against severe acute respiratory syndrome coronavirus 2 infection and severe coronavirus disease 2019 when compared with the 2-dose mRNA-1273 primary series during periods of Delta and Omicron variant predominance.

Md Taufiqul Islam and others
Clinical Infectious Diseases, Volume 76, Issue 2, 15 January 2023, Pages 263–270, https://doi.org/10.1093/cid/ciac782

Co-administration of bivalent oral poliovirus vaccine (bOPV) and oral cholera vaccine (OCV) is safe and effective in children aged 1–3 years and can be cost-beneficial. The study results are useful when bOPV and OCV are likely to be co-administered such as integrated OPV and OCV campaign.

Clinical Trial Registration: ClinicalTrials.gov (NCT03581734)

Uma Siangphoe and others
Clinical Infectious Diseases, Volume 76, Issue 2, 15 January 2023, Pages 271–280, https://doi.org/10.1093/cid/ciac780

The association between immunogenicity and reactogenicity following 2 injections of mRNA-1273 vaccine was assessed in adolescents and adults (≥12 years). mRNA-1273 elicited high neutralizing antibody titers regardless of reactogenicity. Systemic reactogenicity was significantly related to higher antibody titers post–second injection.

Pierre Danneels and others
Clinical Infectious Diseases, Volume 76, Issue 2, 15 January 2023, Pages 281–290, https://doi.org/10.1093/cid/ciac777

This retrospective multicentric study of 279 Enterococcus faecalis endocarditis illustrates that relapses are frequent (1-year rate 9.3%) and can occur more than 1 year after the initial episode. Cardiac surgery and antibiotic combination are cornerstones of treatment to prevent relapse.

Michihiko Goto and others
Clinical Infectious Diseases, Volume 76, Issue 2, 15 January 2023, Pages 291–298, https://doi.org/10.1093/cid/ciac776

A multicenter quasi-experimental study with a stepped-wedge intervention design revealed that enhanced terminal room cleaning with ultraviolet-C disinfection was associated with a lower incidence rate of hospital-onset gram-negative rod bloodstream infection at the facility level.

Charles M Burns and others
Clinical Infectious Diseases, Volume 76, Issue 2, 15 January 2023, Pages 299–306, https://doi.org/10.1093/cid/ciac775

We created machine-learning models to predict incident human immunodeficiency virus (HIV) diagnosis as a marker for pre-exposure prophylaxis (PrEP) candidacy among patients from a southern medical system. The models effectively predicted incident HIV diagnoses and were more effective among women compared to prior models.

Kashif Iqbal and others
Clinical Infectious Diseases, Volume 76, Issue 2, 15 January 2023, Pages 307–314, https://doi.org/10.1093/cid/ciac774

THRIVE collaboratives were associated with decreasing rates of HIV diagnoses for Black and Hispanic/Latino MSM. THRIVE programmatic activities strengthened prevention services by making PrEP accessible to Black and Hispanic/Latino MSM and supporting utilization of PrEP through navigation and other interventions.

Lars Haukali Omland and others
Clinical Infectious Diseases, Volume 76, Issue 2, 15 January 2023, Pages 315–322, https://doi.org/10.1093/cid/ciac773

In this nationwide, population-based cohort study, patients with brain abscess and no evidence of prior psychiatric disorders were at no increased risk of psychiatric disorders. However, we did demonstrate an increased receipt of psychiatric medication.

Markella V Zanni and others
Clinical Infectious Diseases, Volume 76, Issue 2, 15 January 2023, Pages 323–334, https://doi.org/10.1093/cid/ciac767

Among US persons with HIV (PWH), females demonstrated a lower prevalence of subclinical coronary artery disease (CAD), as well as differences in key immune/inflammatory biomarkers. Understanding sex-specific immune drivers of subclinical CAD will facilitate appropriately tailoring cardiovascular disease–preventive therapies to PWH.

Brief Reports

Laith Yakob and others
Clinical Infectious Diseases, Volume 76, Issue 2, 15 January 2023, Pages 335–337, https://doi.org/10.1093/cid/ciac794
Jennifer H Ku and others
Clinical Infectious Diseases, Volume 76, Issue 2, 15 January 2023, Pages 338–341, https://doi.org/10.1093/cid/ciac788
John I Hogan and others
Clinical Infectious Diseases, Volume 76, Issue 2, 15 January 2023, Pages 342–345, https://doi.org/10.1093/cid/ciac769

Viewpoints

Nicolás Cortés-Penfield and Jonathan H Ryder
Clinical Infectious Diseases, Volume 76, Issue 2, 15 January 2023, Pages 346–350, https://doi.org/10.1093/cid/ciac720

Observational data suggest adjunctive clindamycin reduces mortality in severe toxin-mediated Group A Streptococcus (GAS) infections, but GAS clindamycin resistance is increasing. Linezolid is a promising alternative adjunct with similar in vitro antitoxin activity but more limited supporting clinical data.

Review Article

Kevin Chevalier and others
Clinical Infectious Diseases, Volume 76, Issue 2, 15 January 2023, Pages 351–358, https://doi.org/10.1093/cid/ciac649

Hemophagocytic lymphohistiocytosis (HLH) can be triggered by cytomegalovirus (CMV). HLH after CMV infection can occur in immunocompetent patients. CMV infection is nearly always symptomatic, and lung involvement is frequent. Antiviral drugs might be the cornerstone of treatment.

Invited Article

Ravina Kullar and others
Clinical Infectious Diseases, Volume 76, Issue 2, 15 January 2023, Pages 359–364, https://doi.org/10.1093/cid/ciac733

This article describes the gaps in traditional culture and the utility of next-generation sequencing (NGS) in diagnosing and treating peri-prosthetic joint infections. The clinical benefits of NGS compared to culture alone are discussed.

Photo Quiz

H E Groves and others
Clinical Infectious Diseases, Volume 76, Issue 2, 15 January 2023, Pages 365–367, https://doi.org/10.1093/cid/ciac260

Correspondence

Dimitrios P Kontoyiannis
Clinical Infectious Diseases, Volume 76, Issue 2, 15 January 2023, Page 368, https://doi.org/10.1093/cid/ciac710
Joshua Malo and others
Clinical Infectious Diseases, Volume 76, Issue 2, 15 January 2023, Pages 368–369, https://doi.org/10.1093/cid/ciac706
Yi-Ching Chen and others
Clinical Infectious Diseases, Volume 76, Issue 2, 15 January 2023, Pages 369–371, https://doi.org/10.1093/cid/ciac696
Chi-Kuei Hsu and Chih-Cheng Lai
Clinical Infectious Diseases, Volume 76, Issue 2, 15 January 2023, Page 371, https://doi.org/10.1093/cid/ciac691
Aravinda de Silva
Clinical Infectious Diseases, Volume 76, Issue 2, 15 January 2023, Pages 371–372, https://doi.org/10.1093/cid/ciac690

Corrections

Clinical Infectious Diseases, Volume 76, Issue 2, 15 January 2023, Page 373, https://doi.org/10.1093/cid/ciac575
Clinical Infectious Diseases, Volume 76, Issue 2, 15 January 2023, Page 373, https://doi.org/10.1093/cid/ciac576
Clinical Infectious Diseases, Volume 76, Issue 2, 15 January 2023, Page 374, https://doi.org/10.1093/cid/ciac346
Clinical Infectious Diseases, Volume 76, Issue 2, 15 January 2023, Page 374, https://doi.org/10.1093/cid/ciac547
Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close